188 related articles for article (PubMed ID: 26123439)
21. Influence of storage conditions and extraction methods on the quantity and quality of circulating cell-free DNA (ccfDNA): the SPIDIA-DNAplas External Quality Assessment experience.
Malentacchi F; Pizzamiglio S; Verderio P; Pazzagli M; Orlando C; Ciniselli CM; Günther K; Gelmini S
Clin Chem Lab Med; 2015 Nov; 53(12):1935-42. PubMed ID: 25883202
[TBL] [Abstract][Full Text] [Related]
22. Assessment of DNA Integrity, Applications for Cancer Research.
Zonta E; Nizard P; Taly V
Adv Clin Chem; 2015; 70():197-246. PubMed ID: 26231488
[TBL] [Abstract][Full Text] [Related]
23. Comparison of 4 commercial kits for the extraction of circulating DNA from plasma.
Warton K; Graham LJ; Yuwono N; Samimi G
Cancer Genet; 2018 Dec; 228-229():143-150. PubMed ID: 29567030
[TBL] [Abstract][Full Text] [Related]
24. Development and validation of a quantitative real time PCR assay for BK virus.
Mitui M; Leos NK; Lacey D; Doern C; Rogers BB; Park JY
Mol Cell Probes; 2013; 27(5-6):230-6. PubMed ID: 23973570
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of circulating cell free DNA in plasma as a biomarker of different thyroid diseases.
Caglar O; Cilgin B; Eroglu M; Cayir A
Braz J Otorhinolaryngol; 2020; 86(3):321-326. PubMed ID: 30826312
[TBL] [Abstract][Full Text] [Related]
26. Dutch National Round Robin Trial on Plasma-Derived Circulating Cell-Free DNA Extraction Methods Routinely Used in Clinical Pathology for Molecular Tumor Profiling.
van der Leest P; Ketelaar EM; van Noesel CJM; van den Broek D; van Boerdonk RAA; Deiman B; Rifaela N; van der Geize R; Huijsmans CJJ; Speel EJM; Geerlings MJ; van Schaik RHN; Jansen MPHM; Dane-Vogelaar R; Driehuis E; Leers MPG; Sidorenkov G; Tamminga M; van Kempen LC; Schuuring E
Clin Chem; 2022 Jul; 68(7):963-972. PubMed ID: 35616097
[TBL] [Abstract][Full Text] [Related]
27. Circulating cell free DNA: Preanalytical considerations.
El Messaoudi S; Rolet F; Mouliere F; Thierry AR
Clin Chim Acta; 2013 Sep; 424():222-30. PubMed ID: 23727028
[TBL] [Abstract][Full Text] [Related]
28. Circulating cell-free DNA in plasma of melanoma patients: qualitative and quantitative considerations.
Pinzani P; Salvianti F; Zaccara S; Massi D; De Giorgi V; Pazzagli M; Orlando C
Clin Chim Acta; 2011 Nov; 412(23-24):2141-5. PubMed ID: 21839068
[TBL] [Abstract][Full Text] [Related]
29. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer.
Sirera R; Bremnes RM; Cabrera A; Jantus-Lewintre E; Sanmartín E; Blasco A; Del Pozo N; Rosell R; Guijarro R; Galbis J; Sánchez JJ; Camps C
J Thorac Oncol; 2011 Feb; 6(2):286-90. PubMed ID: 21252717
[TBL] [Abstract][Full Text] [Related]
30. Role of cell-free plasma DNA as a diagnostic marker for prostate cancer.
Allen D; Butt A; Cahill D; Wheeler M; Popert R; Swaminathan R
Ann N Y Acad Sci; 2004 Jun; 1022():76-80. PubMed ID: 15251943
[TBL] [Abstract][Full Text] [Related]
31. DNA integrity in plasma and serum of patients with malignant and benign diseases.
Holdenrieder S; Burges A; Reich O; Spelsberg FW; Stieber P
Ann N Y Acad Sci; 2008 Aug; 1137():162-70. PubMed ID: 18837942
[TBL] [Abstract][Full Text] [Related]
32. Efficiency of EGFR mutation analysis for small microdissected cytological specimens using multitech DNA extraction solution.
Oh SY; Lee HT
Cancer Cytopathol; 2015 Jul; 123(7):401-12. PubMed ID: 25964184
[TBL] [Abstract][Full Text] [Related]
33. Quantification of free circulating DNA as a diagnostic marker in lung cancer.
Sozzi G; Conte D; Leon M; Ciricione R; Roz L; Ratcliffe C; Roz E; Cirenei N; Bellomi M; Pelosi G; Pierotti MA; Pastorino U
J Clin Oncol; 2003 Nov; 21(21):3902-8. PubMed ID: 14507943
[TBL] [Abstract][Full Text] [Related]
34. Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy.
Gautschi O; Bigosch C; Huegli B; Jermann M; Marx A; Chassé E; Ratschiller D; Weder W; Joerger M; Betticher DC; Stahel RA; Ziegler A
J Clin Oncol; 2004 Oct; 22(20):4157-64. PubMed ID: 15483026
[TBL] [Abstract][Full Text] [Related]
35. Sensitivity assessment of workflows detecting rare circulating cell-free DNA targets: A study design proposal.
Voss T; Ullius A; Schönborn M; Oelmüller U
PLoS One; 2021; 16(7):e0253401. PubMed ID: 34228726
[TBL] [Abstract][Full Text] [Related]
36. TRIzol and Alu qPCR-based quantification of metastatic seeding within the skeleton.
Preston Campbell J; Mulcrone P; Masood SK; Karolak M; Merkel A; Hebron K; Zijlstra A; Sterling J; Elefteriou F
Sci Rep; 2015 Aug; 5():12635. PubMed ID: 26271202
[TBL] [Abstract][Full Text] [Related]
37. Circulating cell-free DNA in cancer.
Pinzani P; Salvianti F; Orlando C; Pazzagli M
Methods Mol Biol; 2014; 1160():133-45. PubMed ID: 24740228
[TBL] [Abstract][Full Text] [Related]
38. A useful protocol for analyses of mutations of the epidermal growth factor receptor gene.
Liu D; Nakano J; Ueno M; Masuya D; Nakashima T; Yokomise H; Yube K; Huang CL
Oncol Rep; 2006 Jun; 15(6):1503-5. PubMed ID: 16685386
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of fluorescence-based methods for total vs. amplifiable DNA quantification in plasma of lung cancer patients.
Szpechcinski A; Struniawska R; Zaleska J; Chabowski M; Orlowski T; Roszkowski K; Chorostowska-Wynimko J
J Physiol Pharmacol; 2008 Dec; 59 Suppl 6():675-81. PubMed ID: 19218694
[TBL] [Abstract][Full Text] [Related]
40. Comparison study of the performance of the QIAGEN EGFR RGQ and EGFR pyro assays for mutation analysis in non-small cell lung cancer.
Cushman-Vokoun AM; Crowley AM; Rapp SA; Greiner TC
Am J Clin Pathol; 2013 Jul; 140(1):7-19. PubMed ID: 23765529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
